Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioGross MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

NovaBay Pharmaceuticals (NBY) EBITDA Margin (2016 - 2025)

Historic EBITDA Margin for NovaBay Pharmaceuticals (NBY) over the last 17 years, with Q3 2025 value amounting to 241.07%.

  • NovaBay Pharmaceuticals' EBITDA Margin changed N/A to 241.07% in Q3 2025 from the same period last year, while for Sep 2025 it was 41.16%, marking a year-over-year increase of 572400.0%. This contributed to the annual value of 59.7% for FY2024, which is 204600.0% down from last year.
  • Latest data reveals that NovaBay Pharmaceuticals reported EBITDA Margin of 241.07% as of Q3 2025.
  • In the past 5 years, NovaBay Pharmaceuticals' EBITDA Margin registered a high of 2.33% during Q4 2024, and its lowest value of 258.74% during Q4 2022.
  • Its 5-year average for EBITDA Margin is 86.73%, with a median of 78.42% in 2022.
  • Its EBITDA Margin has fluctuated over the past 5 years, first tumbled by -1580800bps in 2022, then skyrocketed by 2107700bps in 2023.
  • Quarter analysis of 5 years shows NovaBay Pharmaceuticals' EBITDA Margin stood at 100.66% in 2021, then tumbled by -157bps to 258.74% in 2022, then soared by 81bps to 47.98% in 2023, then soared by 95bps to 2.33% in 2024, then crashed by -10242bps to 241.07% in 2025.
  • Its EBITDA Margin was 241.07% in Q3 2025, compared to 2.33% in Q4 2024 and 43.88% in Q2 2024.